Ikena Oncology, Inc. 已实施一项1比12的反向股票分割行动，预计于2025年7月底正式生效。这一举措将大幅缩减公司已发行和流通股数，从约4820万股降至约400万股。同时，该公司的普通股将在纳斯达克交易所以分割调整后的基准开始交易。这一时间点恰与预期完成的Inmagene Biopharmaceuticals合并案相吻合。合并后，新实体将更名为ImageneBio, Inc.，并以交易代码“IMA”挂牌。
Ikena Oncology, Inc. 已实施一项1比12的反向股票分割行动，预计于2025年7月底正式生效。这一举措将大幅缩减公司已发行和流通股数，从约4820万股降至约400万股。同时，该公司的普通股将在纳斯达克交易所以分割调整后的基准开始交易。这一时间点恰与预期完成的Inmagene Biopharmaceuticals合并案相吻合。合并后，新实体将更名为ImageneBio, Inc.，并以交易代码“IMA”挂牌。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.